Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma
Acta Pharmaceutica Sinica B · 2026-01 · 16 (1) · 305-321
DOI: 10.1016/j.apsb.2025.10.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-01. Verfasst von Deby Fajar Mardhian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Engineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente,…. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Technology Foundation STW, Egypt Ministry of Higher Education Cultural Affairs and Missions Sector.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Engineered Therapeutics Group, Department of Advanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, University of Twente, Enschede 7500AE, The Netherlands.
- Department of Dental Materials and Technology, Faculty of Dentistry, Padjadjaran University, Bandung 40132, Indonesia.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
- CRUK Scotland Institute, Glasgow G61 1BD, UK.
- ScarTec Therapeutics BV, Horst 2, Enschede 7522LW, The Netherlands.
- Institute for Experimental Molecular Imaging (ExMI), RWTH Aachen University Hospital, Aachen 52074, Germany.
Förderung
- Swedish Research Council
- Technology Foundation STW
- Egypt Ministry of Higher Education Cultural Affairs and Missions Sector
- Lembaga Pengelola Dana Pendidikan
- Cancer Research UK
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Ministry of Higher Education and Scientific Research
Zitieren
APA
Mardhian, D. F., Pednekar, K. P., Hemdan, A. G., Kuninty, P. R., Karim, S. A., de Winter, S., Metselaar, J. M., Morton, J. P., & Prakash, J. (2026). Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma. Acta Pharmaceutica Sinica B, 16(1), 305-321. https://doi.org/10.1016/j.apsb.2025.10.022
Vancouver
Mardhian DF, Pednekar KP, Hemdan AG, Kuninty PR, Karim SA, de Winter S, et al. Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma. Acta Pharmaceutica Sinica B. 2026;16(1):305-321. doi:10.1016/j.apsb.2025.10.022
BibTeX
@article{Mardhian2026,
author = {Mardhian, Deby Fajar and Pednekar, Kunal P and Hemdan, Ahmed G and Kuninty, Praneeth Reddy and Karim, Saadia A and de Winter, Sabine and Metselaar, Josbert M and Morton, Jennifer P and Prakash, Jai},
title = {Engineered cyclic peptide targeting ITGA5 disrupts tumor–stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {1},
pages = {305--321},
doi = {10.1016/j.apsb.2025.10.022}
}
EUVIMED